Eledon Pharmaceuticals (ELDN) Operating Expenses (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Operating Expenses data on file, last reported at $21.2 million in Q1 2026.

• Quarterly Operating Expenses rose 17.91% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 21.61% YoY) and the FY2025 annual result came in at $7.5 million, up 14.23% from the prior year.
• Operating Expenses improved to $21.2 million in Q1 2026, from -$54.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $58.7 million in Q4 2022 to a low of -$54.3 million in Q4 2025.
• A 5-year average of $9.8 million and a median of $11.1 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses jumped 525.34% — and 2024, when it plunged 480.52%.
• Tracing ELDN's Operating Expenses over 5 years: stood at $58.7 million in 2022, then sank by 82.38% to $10.3 million in 2023, then sank by 480.52% to -$39.3 million in 2024, then sank by 38.02% to -$54.3 million in 2025, then jumped by 139.01% to $21.2 million in 2026.
• The last three Operating Expenses figures came in at $21.2 million (Q1 2026), -$54.3 million (Q4 2025), and $19.1 million (Q3 2025), per Business Quant data.